An open-label, phase 2 trial of RPI.4610 in the treatment of metastatic breast cancer

Cancer, 05/07/2012

Most common adverse events (AEs) were: injection site reactions, abdominal pain, anorexia, chromaturia, constipation, dyspnea, fatigue, headache, pain at the injection site, nausea, vomiting, and fever. Although RPI.4610 demonstrated a well–tolerated safety profile, its lack of clinical efficacy precludes this drug from further development.

Print Article Summary Cat 2 CME Report